Indeed, FGF23 signaling promotes proliferation in myeloma cells [123], while increase of FGF23 levels in serum were observed in cancer patients, and were also elevated in patients with non-cancerous diseases, such as hypophosphatemic rickets and chronic kidney diseases [124]. This evidence concerns the gene FGF23 and hypophosphatemic rickets.